Literature DB >> 24852571

Personalized medicine, availability, and group disparity: an inquiry into how physicians perceive and rate the elements and barriers of personalized medicine.

Katelin E Petersen1, Cynthia A Prows, Lisa J Martin, Koffi N Maglo.   

Abstract

BACKGROUND: The success of personalized medicine depends on factors influencing the availability and implementation of its new tools to individualize clinical care. However, little is known about physicians' views of the availability of personalized medicine across racial/ethnic groups and the relationship between perceived availability and clinical implementation. This study examines physicians' perceptions of key elements/tools and potential barriers to personalized medicine in connection with their perceptions of the availability of the latter across subpopulations.
METHODS: Study subjects consisted of physicians recruited from Cincinnati Children's Hospital Medical Center and UC Health. An electronic survey conducted from September 2012 to November 2012 recruited 104 physicians. Wilcoxon rank sum analysis compared groups.
RESULTS: Physicians were divided about whether personalized medicine contributes to health equality, as 37.4% of them believe that personalized medicine is currently available only for some subpopulations. They also rated the importance of racial/ethnic background almost as high as the importance of genetic information in the delivery of personalized medicine. Actual elements of personalized medicine rated highest include family history, drug-drug interaction alerts in medical records, and biomarker measurements to guide therapy. Costs of gene-based therapies and genetic testing were rated the most significant barriers. The ratings of several elements and barriers were associated with perceived availability of personalized medicine across subpopulations.
CONCLUSION: While physicians hold differing views about the availability and implementation of personalized medicine, they likewise establish complex relationships between race/ethnicity and personalized medicine that may carry serious implications for its clinical success.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 24852571     DOI: 10.1159/000362359

Source DB:  PubMed          Journal:  Public Health Genomics        ISSN: 1662-4246            Impact factor:   2.000


  13 in total

1.  Issues associated with a hereditary risk of cancer: Knowledge, attitudes and practices of nurses in oncology settings.

Authors:  Johanne Hébert; Anne-Sophie Bergeron; Anne-Marie Veillette; Karine Bouchard; Hermann Nabi; Michel Dorval
Journal:  Can Oncol Nurs J       Date:  2022-04-01

2. 

Authors:  Johanne Hébert; Anne-Sophie Bergeron; Anne-Marie Veillette; Karine Bouchard; Hermann Nabi; Michel Dorval
Journal:  Can Oncol Nurs J       Date:  2022-04-01

Review 3.  Genetics/genomics education for nongenetic health professionals: a systematic literature review.

Authors:  Divya Talwar; Tung-Sung Tseng; Margaret Foster; Lei Xu; Lei-Shih Chen
Journal:  Genet Med       Date:  2016-10-20       Impact factor: 8.822

4.  Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine.

Authors:  Kayla E Cooper; Khadijah E Abdallah; Rebekah S M Angove; Kathleen D Gallagher; Vence L Bonham
Journal:  Ethn Dis       Date:  2022-01-20       Impact factor: 2.006

Review 5.  Population Genomics and the Statistical Values of Race: An Interdisciplinary Perspective on the Biological Classification of Human Populations and Implications for Clinical Genetic Epidemiological Research.

Authors:  Koffi N Maglo; Tesfaye B Mersha; Lisa J Martin
Journal:  Front Genet       Date:  2016-02-17       Impact factor: 4.599

6.  Identification of Delivery Models for the Provision of Predictive Genetic Testing in Europe: Protocol for a Multicentre Qualitative Study and a Systematic Review of the Literature.

Authors:  Brigid Unim; Tyra Lagerberg; Erica Pitini; Corrado De Vito; Maria Rosaria Vacchio; Giovanna Adamo; Annalisa Rosso; Elvira D'Andrea; Carolina Marzuillo; Paolo Villari
Journal:  Front Public Health       Date:  2017-08-22

Review 7.  Ethical considerations of neuro-oncology trial design in the era of precision medicine.

Authors:  Saksham Gupta; Timothy R Smith; Marike L Broekman
Journal:  J Neurooncol       Date:  2017-05-29       Impact factor: 4.130

8.  Understanding barriers to the introduction of precision medicines in non-small cell lung cancer: A qualitative interview protocol.

Authors:  Stuart Wright; Gavin Daker-White; William Newman; Katherine Payne
Journal:  Wellcome Open Res       Date:  2018-03-08

9.  The clinical impact of using complex molecular profiling strategies in routine oncology practice.

Authors:  Jean-François Laes; Philippe Aftimos; Philippe Barthelemy; Joaquim Bellmunt; Guy Berchem; Carlos Camps; Ramón de Las Peñas; Ana Finzel; Jesús García-Foncillas; Petteri Hervonen; Ibrahim Wahid; Timo Joensuu; Louis Kathan; Anthony Kong; James Mackay; Christos Mikropoulos; Kefah Mokbel; Jean-Loup Mouysset; Sergey Odarchenko; Timothy J Perren; Rika Pienaar; Carlos Regonesi; Shadi Salem Alkhayyat; Abdul Rahman El Kinge; Omalkhair Abulkhair; Khaled Morsi Galal; Hady Ghanem; Fadi El Karak; Angel Garcia; Gregori Ghitti; Helen Sadik
Journal:  Oncotarget       Date:  2018-04-17

10.  Genomics knowledge and attitudes among European public health professionals: Results of a cross-sectional survey.

Authors:  Annalisa Rosso; Erica Pitini; Elvira D'Andrea; Marco Di Marco; Brigid Unim; Valentina Baccolini; Corrado De Vito; Carolina Marzuillo; Floris Barnhoorn; Dineke Zeegers Paget; Paolo Villari
Journal:  PLoS One       Date:  2020-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.